Humira, used to treat rheumatoid arthritis and other conditions, can cost upward of $9,000 a month, according to GoodRx.
The drug’s first biologic competitor, Amjevita, was introduced in 2023. According to Bloomberg, Amjevita is offered at two different prices: around $85,500 a year, about 5 percent less than Humira; and around $40,500 a year, about 55 percent of Humira’s cost.
PBMs are mostly sticking with higher list prices, Bloomberg reported, with policies varying widely across insurers.
CVS Caremark favors Humira, while Express Scripts and OptumRx cover both versions.
At OptumRx, clients can choose between the higher or lower priced versions of Amjevita, trading higher rebates for lower list prices, Bloomberg reported.
Read more here.
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
